We anticipate that addition of more biomarkers to the assay could ultimately provide the necessary diagnostic performance for non-invasive population-wide learn more CRC screening which could complement the expensive, slower and more invasive colonoscopy. The following

are the supplementary data related to this article. Supplemental Fig. 1.   Verifying attachment of recombinant and cell-free produced proteins to VeraCode™ beads. GST-Tagged Recombinant proteins were detected on the VeraCode™ beads using an anti-GST Tag Alexa® Fluor 647 antibody conjugate. The commercial anti-GST Tag antibody (Abcam, Cambridge, MA) was labeled with Alexa® Fluor 647 in the same manner as for biotin labeling of antibodies detailed in the main manuscript body (Materials and Methods Section 2.5), except that the biotin labeling reagent was replaced with Alexa® Fluor 647 Succinimidyl

Ester (Invitrogen, Carlsbad, CA). For recombinant proteins, the “Blank” (background control) shows beads which went through the entire protocol for recombinant protein attachment to the beads except that the protein was omitted from the coupling reaction (but beads still subsequently probed with the antibody). BMN-673 VSV-G-Tagged cell-free expressed proteins were detected on the VeraCode™ beads using a Cy3 conjugated anti-VSV-G-Tag antibody (Sigma-Aldrich, St. Louis, MO). For cell-free proteins, the “Blank” (background control) shows streptavidin beads which were loaded with a “negative” protein synthesis reaction in which only the cognate expression DNA was omitted (but beads still subsequently probed with the antibody). Pregnenolone Grant support This work was funded in part by a Phase I and II SBIR grant (R43/R44 CA137948) from the National Institutes of Health to AmberGen Incorporated.

Authors’ contributions HPO, KJR and MJL contributed to project conception and design. HPO, AA, ZL, ZW, KIB and MJL contributed to development of methodology and analysis and interpretation of data. AA, ZL, ZW and KIB were responsible for data acquisition. HPO, KJR and MJL were responsible for writing and review of the manuscript. “
“Successful strategies to produce human antibodies have involved humanization of rodent monoclonal antibodies (mAbs), selection of antigen-specific human sequences by display technology and the generation of transgenic animals carrying human Ig loci (Green, 1999, Lonberg, 2005, Lonberg, 2008 and Brüggemann et al., 2007).